De Novo device
Cerament G
Bonesupport AB · Filler, Bone Void, Calcium Compound Containing Single Approved Aminoglycoside (QRR, Class II) · First FDA decision May 17, 2022, newest Mar 13, 2024Fractures and orthopedic trauma
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
Breakthrough-designated
Device trials
7
Naming "Cerament G"
MAUDE reports
8
Brand "Cerament G", since 2015
PubMed studies
31
Mentioning "Cerament G"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Cerament G
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- CERAMENT GBreakthrough510(k)
K234008 · Decided Mar 13, 2024 · 85 days after receipt
Device type: Filler, Bone Void, Calcium Compound Containing Single Approved Aminoglycoside (QRR) · Orthopedic Surgery
- CERAMENT GNew device typeBreakthroughDe Novo
DEN210044 · Decided May 17, 2022 · 231 days after receipt
Device type: Filler, Bone Void, Calcium Compound Containing Single Approved Aminoglycoside (QRR) · Orthopedic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Cerament G", any status and sponsor, newest update first.
- CERAMENT G Device RegistryRecruiting
BONESUPPORT ABNot on our public-company list
NCT06010433 · 100 participants (planned) · Start Aug 17, 2023 · Primary completion Sep 22, 2028
Device: CERAMENT G · For: Chronic Osteomyelitis; Fracture Related Infection; Diabetic Foot Osteomyelitis
Sites: San Diego, California; Charlotte, North Carolina; Cleveland, Ohio
Mid and South Essex NHS Foundation TrustAcademic, hospital or other
NCT06628115 · 25 participants · Start Oct 1, 2024 · Primary completion Aug 1, 2026
Device: cerament V or G · For: Osteomyelitis - Foot
Sites: Basildon, United Kingdom
Royal College of Surgeons, IrelandAcademic, hospital or other
NCT07057817 · 30 participants (planned) · Start Jan 1, 2026 · Primary completion Jul 2029
Device: Cerament G · For: Osteomyelitis; Diabetes; Calcanectomy
Sites: Galway, Ireland
4 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Cerament G", and for the whole product code for context.
This brand
8 reports: 3 malfunction, 5 injury, 0 death
Whole product code QRR
8 reports: 3 malfunction, 5 injury, 0 death
Newest reports for this brand
- CERAMENT GInjury
3005304945-2026-00004 · Received Oct 12, 2026 · Event dated Jan 1, 2023
Device type: Filler, Bone Void, Calcium Compound Containing Single Approved Aminoglycoside (QRR)
Device problem as coded: Device Dislodged or Dislocated; Migration
Patient problem as coded: Tissue Breakdown; Insufficient Information
- CERAMENT GInjury
3005304945-2026-00002 · Received Mar 2, 2026 · Event dated Dec 3, 2025
Device type: Filler, Bone Void, Calcium Compound Containing Single Approved Aminoglycoside (QRR)
Device problem as coded: Adverse Event Without Identified Device or Use Problem; No Apparent Adverse Event; Prophylactic removal due to corrective action
Patient problem as coded: Fever; Hematoma; High White Blood Cell Count
- CERAMENT GInjury
3005304945-2026-00001 · Received Feb 13, 2026 · Event dated Jan 27, 2026
Device type: Filler, Bone Void, Calcium Compound Containing Single Approved Aminoglycoside (QRR)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Wound Dehiscence; Infiltration into Tissue; Inflammation
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Cerament G"[tiab]. The summary above synthesizes these.
- Radiological Analysis of Gentamicin Eluting Synthetic Bone Graft Substitute Used in the Management of Patients With Traumatic Bone Voids.
Aljawadi A, Naylor T, Islam A, et al. · Cureus · 2022
- In Vitro Elution of Gentamicin from CERAMENT® G Has an Antimicrobial Effect on Bacteria With Various Levels of Gentamicin Resistance Found in Fracture-related Infection.
Bezstarosti H, Van Lieshout EMM, Van den Hurk MJB, et al. · Clin Orthop Relat Res · 2024
- Ceramic composite with gentamicin decreases persistent infection and increases bone formation in a rat model of debrided osteomyelitis.
Dvorzhinskiy A, Perino G, Chojnowski R, et al. · J Bone Jt Infect · 2021
- [Augmentation in surgical sepsis : Chances and limitations in the treatment of osteitis with calcium hydroxyapatite containing antibiotics].
Freischmidt H, Reiter G, Grützner PA, et al. · Unfallchirurgie (Heidelb) · 2022Review
- Adjuvant local antibiotic prophylaxis in Gustilo-Anderson IIIb open fractures: up to 10 years follow-up on clinical outcomes and complications.
Asano E, Hemat H, Bin Sahl A, et al. · J Orthop Surg Res · 2025
- The Efficacy of Calcium Sulfate/Hydroxyapatite (CaS/HA) Gentamicin in Osteomyelitis Treatment: A Case Series.
Hoveidaei AH, Shahul S, Esmaeili S, et al. · Antibiotics (Basel) · 2024
- Cost-effectiveness of a bone substitute delivering gentamicin in the treatment of chronic osteomyelitis of long bones: Protocol for the CONVICTION randomized multicenter study.
Serrier H, Huot L, Brosset S, et al. · Front Med (Lausanne) · 2023
- Clinical and functional outcomes of the silo technique in the management of diabetic calcaneal osteomyelitis.
Nurhashim N, Tai KM, Kafagi AH, et al. · Cardiovasc Diabetol Endocrinol Rep · 2025
- Outcome Analysis of the Use of Cerament® in Patients with Chronic Osteomyelitis and Corticomedullary Defects.
Niemann M, Graef F, Ahmad SS, et al. · Diagnostics (Basel) · 2022
- Long-Term Follow-Up of Open Gustilo-Anderson IIIB Fractures Treated With an Adjuvant Local Antibiotic Hydroxyapatite Bio-Composite.
Henry JA, Ali A, Elkhidir IH, et al. · Cureus · 2023
- Mycobacterium fortuitum osteomyelitis of the cuboid bone treated with CERAMENT G and V: a case report.
Fraga K, Maireles M, Jordan M, et al. · J Bone Jt Infect · 2022Case Reports
- Adjuvant antibiotic loaded bio composite in the management of diabetic foot osteomyelitis - A multicentre study.
Niazi NS, Drampalos E, Morrissey N, et al. · Foot (Edinb) · 2019Multicenter Study
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.